1. Home
  2. KROS vs NDMO Comparison

KROS vs NDMO Comparison

Compare KROS & NDMO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KROS
  • NDMO
  • Stock Information
  • Founded
  • KROS 2015
  • NDMO 2019
  • Country
  • KROS United States
  • NDMO United States
  • Employees
  • KROS N/A
  • NDMO N/A
  • Industry
  • KROS Biotechnology: Pharmaceutical Preparations
  • NDMO Trusts Except Educational Religious and Charitable
  • Sector
  • KROS Health Care
  • NDMO Finance
  • Exchange
  • KROS Nasdaq
  • NDMO Nasdaq
  • Market Cap
  • KROS 589.8M
  • NDMO 596.2M
  • IPO Year
  • KROS 2020
  • NDMO N/A
  • Fundamental
  • Price
  • KROS $10.86
  • NDMO $10.37
  • Analyst Decision
  • KROS Buy
  • NDMO
  • Analyst Count
  • KROS 11
  • NDMO 0
  • Target Price
  • KROS $45.33
  • NDMO N/A
  • AVG Volume (30 Days)
  • KROS 2.0M
  • NDMO 218.6K
  • Earning Date
  • KROS 02-26-2025
  • NDMO 01-01-0001
  • Dividend Yield
  • KROS N/A
  • NDMO 6.75%
  • EPS Growth
  • KROS N/A
  • NDMO N/A
  • EPS
  • KROS N/A
  • NDMO N/A
  • Revenue
  • KROS $651,000.00
  • NDMO N/A
  • Revenue This Year
  • KROS $303.39
  • NDMO N/A
  • Revenue Next Year
  • KROS N/A
  • NDMO N/A
  • P/E Ratio
  • KROS N/A
  • NDMO N/A
  • Revenue Growth
  • KROS 8037.50
  • NDMO N/A
  • 52 Week Low
  • KROS $9.78
  • NDMO $8.99
  • 52 Week High
  • KROS $73.00
  • NDMO $11.24
  • Technical
  • Relative Strength Index (RSI)
  • KROS 20.25
  • NDMO 57.84
  • Support Level
  • KROS $9.78
  • NDMO $10.08
  • Resistance Level
  • KROS $16.49
  • NDMO $10.25
  • Average True Range (ATR)
  • KROS 0.92
  • NDMO 0.11
  • MACD
  • KROS 0.97
  • NDMO 0.05
  • Stochastic Oscillator
  • KROS 14.52
  • NDMO 100.00

About KROS Keros Therapeutics Inc.

Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.

About NDMO Nuveen Dynamic Municipal Opportunities Fund of Beneficial Interest

Nuveen Dynamic Municipal Opportunities is a closed-end management investment company. The investment objective of the Fund is to seek total return through income exempt from regular federal income taxes and capital appreciation.

Share on Social Networks: